首页/数据集/Experimental validation of druggable epigenetic targets in hepatoblastoma

Experimental validation of druggable epigenetic targets in hepatoblastoma

NIAID Data Ecosystem2026-05-01 收录

肝母细胞瘤表观遗传治疗

肿瘤药物靶点验证

数据链接：

https://www.ncbi.nlm.nih.gov/sra/SRP407186 数据链接链接失效反馈

官方服务：

资源简介：

Huh6 and HepT1 cell lines treated with G9a-DNMT1 dual inhibitor CM272 (n=3)

应用场景：

创建时间：

2023-04-29

神经退行性疾病模型

肿瘤药物靶点验证

Alzheimer’s disease (AD) is the most common neurodegenerative disease which is becoming increasingly prevalent due to ageing populations resulting in huge social, economic, and health costs to the com

NIAID Data Ecosystem100

Thermal Shift Assay Data

蛋白质稳定性

肿瘤药物靶点验证

https://pubmed.ncbi.nlm.nih.gov/33479120/

Figshare2024-05-20 更新30

Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment. Homo sapiens

癌症表观遗传学

肿瘤药物靶点验证

Ezh2 protein is the enzymatic component of the Polycomb Repressive Complex (PRC)-2, which represses its target genes by methylating lysine 27 of histone H3 (H3K27) and regulates cell proliferation and

NIAID Data Ecosystem10

BindingDB Entry 50018569: Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation.

肿瘤药物靶点验证

抑制剂筛选

Small molecule binding data for protein CTP synthase 1 and CTP synthase 2, Uniprot P17812, P70303, P70698, Q5U2N0, and Q9NRF8

DataCite Commons2024-04-26 更新90

Salt Bridges interactions of the ligands MSID000152, MSID000974, and Control with the target protein GluRS.

蛋白质-配体相互作用

肿瘤药物靶点验证

Salt Bridges interactions of the ligands MSID000152, MSID000974, and Control with the target protein GluRS.

Figshare2025-12-04 更新20